IGXT Intelgenx Techs Corp

0.47
+0.01  (+2%)
Previous Close 0.46
Open 0.46
Price To Book 15.67
Market Cap 43,957,913
Shares 93,942,653
Volume 93,437
Short Ratio
Av. Daily Volume 196,052
Stock charts supplied by TradingView

NewsSee all news

  1. IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

    - Ongoing BUENA Trial to Continue at Increased Daily Dose - SAINT LAURENT, Quebec, Jan. 15, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a leader in pharmaceutical films, today

  2. IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

    SAINT LAURENT, Quebec, Jan. 13, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a leader in pharmaceutical films, today provided a commercial update on its two lead product candidates,

  3. IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

    SAINT LAURENT, Quebec, Jan. 09, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx") a leader in pharmaceutical films, today announced that it has entered into a Feasibility Study Agreement

  4. IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

    SAINT LAURENT, Quebec, Dec. 19, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") is pleased to announce that it has filed a preliminary short form prospectus

  5. IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

    SAINT LAURENT, Quebec, Dec. 06, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") announces that it intends to issue 415,178 common shares of the Corporation

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date March 26, 2020.
RIZAPORT (RHB-103)
Migraine

Latest News

  1. IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

    - Ongoing BUENA Trial to Continue at Increased Daily Dose - SAINT LAURENT, Quebec, Jan. 15, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a leader in pharmaceutical films, today

  2. IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

    SAINT LAURENT, Quebec, Jan. 13, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a leader in pharmaceutical films, today provided a commercial update on its two lead product candidates,

  3. IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

    SAINT LAURENT, Quebec, Jan. 09, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx") a leader in pharmaceutical films, today announced that it has entered into a Feasibility Study Agreement

  4. IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

    SAINT LAURENT, Quebec, Dec. 19, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") is pleased to announce that it has filed a preliminary short form prospectus

  5. IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

    SAINT LAURENT, Quebec, Dec. 06, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") announces that it intends to issue 415,178 common shares of the Corporation

  6. Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th

    CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual

  7. IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    SAINT LAURENT, Quebec, Dec. 03, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that

  8. IntelGenx Reports Third Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported financial

  9. IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, Nov. 01, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it

  10. IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product

    SAINT LAURENT, Quebec, Oct. 31, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has progressed

  11. IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial

    - With No Safety Concerns, DSMB Recommends Trial Continues; Dose Increase Planned - SAINT LAURENT, Quebec, Oct. 09, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or

  12. IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

    SAINT LAURENT, Quebec, Sept. 26, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has resubmitted

  13. IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAINT LAURENT, Quebec, Sept. 03, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its